TrialArthritis research & therapy2026

Impact of symptom duration on the short- and long-term efficacy of bimekizumab in axial spondyloarthritis: results up to 2 years.

Sofia Ramiro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.